Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 574

Cited In for PubMed (Select 18669428)

1.

Association between XRCC1 Arg399Gln polymorphism and glioma risk in a Chinese population: a case-control study.

Wang L, Jiang YQ, Zhou MD, Jiang Z.

Int J Clin Exp Med. 2015 Jun 15;8(6):10026-10030. eCollection 2015.

PMID:
26309694
2.

Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.

Mukthavaram R, Ouyang X, Saklecha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M, Kesari S.

J Transl Med. 2015 Aug 18;13:269. doi: 10.1186/s12967-015-0627-5.

3.

The Use of Three Long Non-Coding RNAs as Potential Prognostic Indicators of Astrocytoma.

Zhi F, Wang Q, Xue L, Shao N, Wang R, Deng D, Wang S, Xia X, Yang Y.

PLoS One. 2015 Aug 7;10(8):e0135242. doi: 10.1371/journal.pone.0135242. eCollection 2015.

4.

Glioma Association and Balancing Selection of ZFPM2.

Tsang SY, Mei L, Wan W, Li J, Li Y, Zhao C, Ding X, Pun FW, Hu X, Wang J, Zhang J, Luo R, Cheung ST, Leung GK, Poon WS, Ng HK, Zhang L, Xue H.

PLoS One. 2015 Jul 24;10(7):e0133003. doi: 10.1371/journal.pone.0133003. eCollection 2015.

5.

Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma.

Wang B, Li M, Wu Z, Li X, Li YU, Shi X, Cheng W.

Exp Ther Med. 2015 Jul;10(1):88-96. Epub 2015 May 12.

6.

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.

Yang L, Guo G, Niu XY, Liu J.

Biomed Res Int. 2015;2015:717530. doi: 10.1155/2015/717530. Epub 2015 Jun 17. Review.

7.

Dynamic epigenetic regulation of glioblastoma tumorigenicity through LSD1 modulation of MYC expression.

Kozono D, Li J, Nitta M, Sampetrean O, Gonda D, Kushwaha DS, Merzon D, Ramakrishnan V, Zhu S, Zhu K, Matsui H, Harismendy O, Hua W, Mao Y, Kwon CH, Saya H, Nakano I, Pizzo DP, VandenBerg SR, Chen CC.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4055-64. doi: 10.1073/pnas.1501967112. Epub 2015 Jul 9.

PMID:
26159421
8.

RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells.

Orozco-Morales M, Sánchez-García FJ, Golán-Cancela I, Hernández-Pedro N, Costoya JA, de la Cruz VP, Moreno-Jiménez S, Sotelo J, Pineda B.

Cancer Cell Int. 2015 Jun 5;15:57. doi: 10.1186/s12935-015-0209-x. eCollection 2015.

9.

Expression of β-transducin repeat-containing E3 ubiquitin protein ligase in human glioma and its correlation with prognosis.

Liang J, Wang WF, Xie S, Zhang XL, Qi WF, Zhou XP, Hu JX, Shi Q, Yu RT.

Oncol Lett. 2015 Jun;9(6):2651-2656. Epub 2015 Apr 14.

10.

Decreased Expression of MiRNA-204-5p Contributes to Glioma Progression and Promotes Glioma Cell Growth, Migration and Invasion.

Xia Z, Liu F, Zhang J, Liu L.

PLoS One. 2015 Jul 2;10(7):e0132399. doi: 10.1371/journal.pone.0132399. eCollection 2015.

11.

Neovibsanin B inhibits human malignant brain tumor cell line proliferation and induces apoptosis.

Cui YF, Yuan XL, Fan WH, Li SF, Deng YQ, Zhang Q, Zhang CL, Yang Z.

Int J Clin Exp Med. 2015 Apr 15;8(4):6456-62. eCollection 2015.

12.

In vitro studies of phenethyl isothiocyanate against the growth of LN229 human glioma cells.

Su JC, Lin K, Wang Y, Sui SH, Gao ZY, Wang ZG.

Int J Clin Exp Pathol. 2015 Apr 1;8(4):4269-76. eCollection 2015.

13.

A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.

Zhang Y, Sun X, Huang M, Ke Y, Wang J, Liu X.

Drug Des Devel Ther. 2015 Jun 11;9:2947-59. doi: 10.2147/DDDT.S79475. eCollection 2015.

14.

Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.

Nigim F, Cavanaugh J, Patel AP, Curry WT Jr, Esaki S, Kasper EM, Chi AS, Louis DN, Martuza RL, Rabkin SD, Wakimoto H.

J Neuropathol Exp Neurol. 2015 Jul;74(7):710-22. doi: 10.1097/NEN.0000000000000210.

PMID:
26083570
15.

A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells.

Mao DD, Gujar AD, Mahlokozera T, Chen I, Pan Y, Luo J, Brost T, Thompson EA, Turski A, Leuthardt EC, Dunn GP, Chicoine MR, Rich KM, Dowling JL, Zipfel GJ, Dacey RG, Achilefu S, Tran DD, Yano H, Kim AH.

Cell Rep. 2015 Jun 23;11(11):1809-21. doi: 10.1016/j.celrep.2015.05.027. Epub 2015 Jun 11.

16.

Ubiquitin-protein ligase E3C promotes glioma progression by mediating the ubiquitination and degrading of Annexin A7.

Pan SJ, Zhan SK, Ji WZ, Pan YX, Liu W, Li DY, Huang P, Zhang XX, Cao CY, Zhang J, Bian LG, Sun B, Sun QF.

Sci Rep. 2015 Jun 11;5:11066. doi: 10.1038/srep11066.

17.

International Differences in Treatment and Clinical Outcomes for High Grade Glioma.

Chien LN, Ostrom QT, Gittleman H, Lin JW, Sloan AE, Barnett GH, Elder JB, McPherson C, Warnick R, Chiang YH, Lin CM, Rogers LR, Chiou HY, Barnholtz-Sloan JS.

PLoS One. 2015 Jun 10;10(6):e0129602. doi: 10.1371/journal.pone.0129602. eCollection 2015.

18.

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.

Westhoff MA, Karpel-Massler G, Brühl O, Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L, Debatin KM.

Mol Cell Ther. 2014 Oct 27;2:32. doi: 10.1186/2052-8426-2-32. eCollection 2014. Review.

19.

Gene therapy for malignant glioma.

Okura H, Smith CA, Rutka JT.

Mol Cell Ther. 2014 Jul 8;2:21. doi: 10.1186/2052-8426-2-21. eCollection 2014. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk